Taking into account the spectacular success of anti-programmedcell death protein 1 (anti-PD-1) or anti-programmed death ligand 1(anti-PD-L1) monoclonal antibodies and their clinical outcomes, itseems that cancer immunotherapy may soon become the first-line treatmentfor a broad spectrum of tumors.1,2 There are multiple immunecheckpoints that regulate the activity of the immune system againstcancer cells. The gene discussed is CD274; the disease is cancer.